Our site uses cookies to improve the contents of the site and customize it according to individual use. Please confirm that you agree to our use of cookies by clicking Yes.

If you continue without explicit consent, we will assume that you agree to our cookie policy.

MEDISOA comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

厚生労働省

Knowledgeable experts support the practical application of medicines, medical devices, and regenerative medicinal products.

NEWS

2018.03.01
Opend the New our homepage!

What is MEDISO

MEDISO provides support for business ventures, academia,
and individuals intending to put into practical use medicines,
medical devices, and regenerative medicinal products.
Click here for further details.

About the Medical Innovation Support Office

The medical innovation support office matches medical venture companies and academic institutions facing challenges in the practical application of medical products and devices for specialists* who provide detailed consultation and support for solving problems at each stage from research and development to practical use, as well as insurance coverage at clinical sites, while looking ahead to the overall comprehensive advances and dissemination into the global market.
* Specialists in each field provide support for the response to laws and regulations, marketing, business planning, fund rasing, management strategy, intellectual property management, and international development, etc.

This website is operated by Mitsubishi Research Institute, Inc., as a trustee under instructions from the Economic Affairs Division, Health Policy Bureau, and Ministry of Health, Labour and Welfare as a part of the total support for the medical ventures program sponsored by the Ministry of Health, Labour and Welfare.

Support targets

Ventures, academic institutions, and individuals aiming to put into practical use the medicines, medical devices, regenerative medicinal products, and novel drug-discovery technologies or medical materials subject to the Pharmaceuticals and Medical Devices Law.

Details of support

MEDISO provides support for the practical application of medicines, medical devices, regenerative medicinal products, and other products subject to the Pharmaceuticals and Medical Devices Law.
That support includes business planning, financing, advice on laws and regulations, and other assistance as required.

Click here for inquiries and consultation requests

Specialists Introduction

We will introduce registered specialists (updated as necessary).

Hiroyuki Hasegawa

Director of Life Science, Mitsubishi UFJ Capital Co., Ltd.

Main specialty areas

  • medicines
  • medical devices
  • regenerative medicine products

Specialized support fields

  • Regulatory compliance
  • Marketing
  • Business planning
  • Funding
  • Business operation systems

He graduated with a master’s degree from the Faculty of Pharmaceutical Sciences, Hokkaido University. In 1994, he joined Daiichi Seiyaku Company (current Daiichi Sankyo Company, Limited) and was in charge of the areas of infectious diseases and cancers in the Department of Post-marketing Surveillance. In 2004, he joined UFJ Capital Co., Ltd. (current Mitsubishi UFJ Capital Co., Ltd.), where he served as an analyst and capitalist. From 2013, he made an attempt to use open innovation for the Development of Emerging Technologies (OiDE) Fund for the purpose of nurturing outcomes from academia-launched research to become the fundamental technology for drug discovery in collaboration with Daiichi Sankyo Company Limited. He promoted investment activities using Mitsubishi UFJ Life Science Number 1 Fund (10 billion yen) established in 2017.

Currently, he holds the position of outside director at OiDE CapiSEA Company, OiDE Adjubilee Company, and Kamuipharma Co. JP., as well as serving as a fellow for collaboration between industry and academia at Kyoto University Medical Science and Business Liaison Organization.

Kenichi Yamahara

Associate Professor at the Pharmaceutical Research and Development Department of Institute for Advanced Medical Sciences, Hyogo College of Medicine
Associate Professor at the Hematology Department of Blood Transfusion & Cell Therapy Center, Hyogo College of Medicine (additional post)
Director of Japan Biomedical Co., Ltd.
Director of CTEX Co., Ltd.

Main specialty areas

  • regenerative medicine products

Specialized support fields

  • Regulatory compliance
  • Marketing
  • Business planning
  • Business operation systems
  • Specialized support fields

From the time of a former position at the National Cerebral and Cardiovascular Center, he planned and implemented the formulation of the amnion-derived mesenchymal stem cells and investigator-initiated clinical trials for acute grafts versus host disease/Crohn's disease in cooperation with Hokkaido University Hospital under the support by Health and Labour Sciences Research Grants/AMED. He often had PMDA consultations on the products of regenerative medicine and acquired knowledge of laws and regulations. Taking advantage of the experience, he founded a venture, Japan Biomedical Co., Ltd., which manufactures the domestic bovine serum NeoSERA® for the products of regenerative medicine by satisfying the standards for biological materials in January 2017. Furthermore, in order to aggressively develop investigator-initiated clinical trials of cell therapy making use of university hospital infrastructures, he founded a venture, CTEX Co., Ltd., from Hyogo College of Medicine in February 2018. Recently, he participated as a medical expert in company clinical trials of the products of regenerative medicine. Currently, he is working on the practice of cell therapy development initiated at the university hospital while concurrently serving in the basic and clinical departments of Hyogo College of Medicine.

Masanobu Naruto

Representative, Phronesystems (consulting)
Senior Research Fellow, Toray Corporate Business Research, Inc.

Main specialty areas

  • medicines
  • medical devices
  • regenerative medicine products

Specialized support fields

  • Marketing
  • Business planning
  • Funding
  • Business operation systems

He has experienced and learned from many failures and successes through his career of research, planning, business development and business operation, which include co-development with domestic and global companies. In his experiences with startup companies, including opposite extremes of excellent bio-ventures and unsuccessful bio-ventures gave him practical wisdom of startup management. He was involved in the evaluation and review of about 90 startup companies at venture capital institutions. He graduated with a master's and doctoral degree in chemistry from Osaka University. He studied abroad at the Department of Molecular Biology, University of California, Berkeley, for two years. At Toray Industries, Inc., he contributed to R&D, business development and business operation of pharmaceuticals, serving as general manager(s) of several divisions including Regulatory Compliance Division, Pharmaceutical Research Laboratories, and Pharmaceuticals Division. After retiring from Toray, he has been working in the consulting business, and serving as Senior Research Fellow at Toray Corporate Business Research, Inc. and committee member at several public institutions for R&D. He has published 38 academic papers in English (total citation, 2090) and 37 opinion articles on research and development in Japanese journals.

Masaya Nakano

Global Business Development Institute, Inc.

Main specialty areas

  • medicines
  • medical devices
  • regenerative medicine products

Specialized support fields

  • Marketing
  • Business planning
  • Business operation systems

He graduated with a master's degree in applied chemistry from the Department of Applied Chemistry, Graduate School of Science and Engineering, Waseda University. He provided survey and consulting services, such as marketing surveys, business planning, and overseas business development support, as an employee of Mitsubishi Research Institute, Inc. In 2012, he became independent and established the Global Business Development Institute, Inc., serving as the representative director. As a small and medium enterprise (SME) management consultant, he provided survey and consulting services in support of SMEs and venture companies.
Work experience
・ Survey and analysis services related to overseas medical needs and the status of overseas business development by domestic companies
・ Formulation of management corrective action programs for small and medium enterprises and monitoring of the implementation
・ Support for overseas business development by venture companies
・ Miscellaneous achievements in marketing surveys and business planning

Takato Noumi

Representative Director, FORESIGHT&LINX Cp., Ltd.

Main specialty areas

  • medicines

Specialized support fields

  • Business planning
  • Funding
  • Business operation systems

At his consulting company, he is currently providing practical support for constructing research strategies, business development, and licensing regarding to drug discovery to pharmaceutical companies and biotech venture companies in Japan and overseas. After completing his postgraduate course, he worked in basic research in molecular biology for 10 years followed by joining the Research Division of the headquarters of Novartis. Subsequently he served as the head of theTsukuba Research Laboratories of GlaxoSmithKline K.K. He had engaged in drug discovery research from a global point of view for 15 years. After that, he has been involved in searching for and evaluating drug discovery seeds and technologies and developing international businesses and licensing at Sanofi S.A. in France and his own consulting company for 10 years. He has a broad network of connections with pharmaceutical companies, biotech venture companies, academia, and venture capital firms in Japan and overseas.

About details of specialists

Introduction of measures implemented by public institutions

We will describe the measures from public institutions for pharmaceutical companies,
medical device companies, companies manufacturing regenerative medicinal products, and venture companies.

See more about measures implemented by public institutions